This new approach shifted the definition of AD in living people from a syndromal to a biological construct and focused the diagnosis of AD on biomarkers in living persons by means of the measure of β amyloid deposition, pathologic tau, and neurodegeneration from biofluids and imaging (9). This evidence concerns the gene MAPT and Alzheimer disease.